File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12072-021-10213-7
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test
Title | Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test |
---|---|
Authors | |
Issue Date | 2021 |
Publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 |
Citation | The 30th Asian Pacific Association for The Study of Liver (APASL) 2021, Virtual Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S1 How to Cite? |
Abstract | Background: We assessed the effect of hepatitis B surface antigen (HBsAg) seroclearance on liver fibrosis regression in patients with chronic hepatitis B (CHB). Method: CHB patients with recent spontaneous HBsAg seroclearance (cases) were age- and gender- matched with treatment-naïve HBeAg-negative CHB infection (controls). Paired transient elastography (TE) and Enhanced Liver Fibrosis (ELF) measurements were performed at baseline and 3-year. Fibrosis progression and regression were defined as increase and decrease in ≥1 fibrosis stage, respectively. Results: In this interim analysis, 40 cases and 142 controls were recruited [median age 55.6 (interquartile range, IQR 49.8-60.9), 53.8% male]. The median liver stiffness (LS) values were similar between the two groups at baseline (5.4 vs. 5.2 kPa, P=0.765) and at 3-years (5.9 vs. 5.5 kPa, P=0.455) respectively. The baseline controlled attenuation parameter values were significantly higher in cases vs controls (288 vs 251 dB/m, respectively, P=0.001). The median ELF at 3-year was significantly higher than baseline in the controls (8.6 vs. 8.4, P=0.033). All patients with severe steatosis had significantly higher baseline LS (5.9 vs. 4.8 kPa; P<0.001), 3-year LS (6.4 vs 5.2 kPa; P<0.001), and baseline ELF (8.8 vs. 8.3, P=0.028). The proportion of patients with fibrosis progression (25.6% vs. 15.5%, respectively, P=0.111) and regression (10.3% vs. 14.8%, P=0.604) was similar in cases vs controls. Conclusion: Over a period of 3 years, fibrosis regression and progression were observed at a similar rate in patients with HBsAg seroclearance compared to patients with inactive CHB. Severe hepatic steatosis was associated with higher LS and ELF. Grant support: Health and Medical Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region, The People's Republic of China (HMRF project number: 16171251) |
Description | YIA: Acute Liver Failure and Artificial Liver Support - no. 1 |
Persistent Identifier | http://hdl.handle.net/10722/300708 |
ISSN | 2023 Impact Factor: 5.9 2023 SCImago Journal Rankings: 1.813 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Hui, WHR | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Liu, F | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2021-06-18T14:55:55Z | - |
dc.date.available | 2021-06-18T14:55:55Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | The 30th Asian Pacific Association for The Study of Liver (APASL) 2021, Virtual Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S1 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | http://hdl.handle.net/10722/300708 | - |
dc.description | YIA: Acute Liver Failure and Artificial Liver Support - no. 1 | - |
dc.description.abstract | Background: We assessed the effect of hepatitis B surface antigen (HBsAg) seroclearance on liver fibrosis regression in patients with chronic hepatitis B (CHB). Method: CHB patients with recent spontaneous HBsAg seroclearance (cases) were age- and gender- matched with treatment-naïve HBeAg-negative CHB infection (controls). Paired transient elastography (TE) and Enhanced Liver Fibrosis (ELF) measurements were performed at baseline and 3-year. Fibrosis progression and regression were defined as increase and decrease in ≥1 fibrosis stage, respectively. Results: In this interim analysis, 40 cases and 142 controls were recruited [median age 55.6 (interquartile range, IQR 49.8-60.9), 53.8% male]. The median liver stiffness (LS) values were similar between the two groups at baseline (5.4 vs. 5.2 kPa, P=0.765) and at 3-years (5.9 vs. 5.5 kPa, P=0.455) respectively. The baseline controlled attenuation parameter values were significantly higher in cases vs controls (288 vs 251 dB/m, respectively, P=0.001). The median ELF at 3-year was significantly higher than baseline in the controls (8.6 vs. 8.4, P=0.033). All patients with severe steatosis had significantly higher baseline LS (5.9 vs. 4.8 kPa; P<0.001), 3-year LS (6.4 vs 5.2 kPa; P<0.001), and baseline ELF (8.8 vs. 8.3, P=0.028). The proportion of patients with fibrosis progression (25.6% vs. 15.5%, respectively, P=0.111) and regression (10.3% vs. 14.8%, P=0.604) was similar in cases vs controls. Conclusion: Over a period of 3 years, fibrosis regression and progression were observed at a similar rate in patients with HBsAg seroclearance compared to patients with inactive CHB. Severe hepatic steatosis was associated with higher LS and ELF. Grant support: Health and Medical Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region, The People's Republic of China (HMRF project number: 16171251) | - |
dc.language | eng | - |
dc.publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 | - |
dc.relation.ispartof | Hepatology International | - |
dc.relation.ispartof | The 30th Asian Pacific Association for the Study of Liver (APASL) Annual Meeting, 2021 | - |
dc.title | Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Hui, WHR: huirex@connect.hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | abstract | - |
dc.identifier.hkuros | 322882 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | S1 | - |
dc.identifier.epage | S1 | - |
dc.publisher.place | India | - |
dc.identifier.partofdoi | 10.1007/s12072-021-10213-7 | - |